Zanidatamab plus chemo showed promising responses in HER2+ and HER2-low mBC, with durable activity in a phase I trial.
HER2 Breast Cancer
Advertisement
Higher fat mass and lower fat density linked to increased T-DXd dose reductions and toxicity in metastatic breast cancer.
Pembrolizumab plus dual HER2 blockade may offer a chemo-free option for early HER2+ breast cancer, phase 2 data suggest.
Enhertu plus THP improved pCR over standard chemo in high-risk HER2+ early breast cancer, DESTINY-Breast11 shows.
New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy.
A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication.
Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer.
Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer.
Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions.
Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer.
Enhertu plus pertuzumab significantly improved PFS vs. THP in 1L HER2+ mBC, marking the first advance in over a decade.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.